Skip to main content
Top
Published in: Diabetologia 4/2009

01-04-2009 | Article

Insulin counteracts glucotoxic effects by suppressing thioredoxin-interacting protein production in INS-1E beta cells and in Psammomys obesus pancreatic islets

Authors: M. Shaked, M. Ketzinel-Gilad, Y. Ariav, E. Cerasi, N. Kaiser, G. Leibowitz

Published in: Diabetologia | Issue 4/2009

Login to get access

Abstract

Aims/hypothesis

In type 2 diabetes, glucose toxicity leads to beta cell apoptosis with decreased beta cell mass as a consequence. Thioredoxin-interacting protein (TXNIP) is a critical mediator of glucose-induced beta cell apoptosis. Since hyperglycaemia leads to elevated serum insulin, we hypothesised that insulin is involved in the regulation of TXNIP protein levels in beta cells.

Methods

We studied the production of TXNIP in INS-1E beta cells and in islets of Psammomys obesus, an animal model of type 2 diabetes, in response to glucose and different modulators of insulin secretion.

Results

TXNIP production was markedly augmented in islets from diabetic P. obesus and in beta cells exposed to high glucose concentration. In contrast, adding insulin to the culture medium or stimulating insulin secretion with different secretagogues suppressed TXNIP. Inhibition of glucose and fatty acid-stimulated insulin secretion with diazoxide increased TXNIP production in beta cells. Nitric oxide (NO), a repressor of TXNIP, enhanced insulin signal transduction, whereas inhibition of NO synthase abolished its activation, suggesting that TXNIP inhibition by NO is mediated by stimulation of insulin signalling. Treatment of beta cells chronically exposed to high glucose with insulin reduced beta cell apoptosis. Txnip knockdown mimicking the effect of insulin prevented glucose-induced beta cell apoptosis.

Conclusions/interpretation

Insulin is a potent repressor of TXNIP, operating a negative feedback loop that restrains the stimulation of TXNIP by chronic hyperglycaemia. Repression of TXNIP by insulin is probably an important compensatory mechanism protecting beta cells from oxidative damage and apoptosis in type 2 diabetes.
Appendix
Available only for authorised users
Literature
1.
go back to reference Prentki M, Nolan CJ (2006) Islet beta cell failure in type 2 diabetes. J Clin Invest 116:1802–1812PubMedCrossRef Prentki M, Nolan CJ (2006) Islet beta cell failure in type 2 diabetes. J Clin Invest 116:1802–1812PubMedCrossRef
2.
go back to reference Kaiser N, Leibowitz G, Nesher R (2003) Glucotoxicity and beta-cell failure in type 2 diabetes mellitus. J Pediatr Endocrinol Metab 16:5–22PubMed Kaiser N, Leibowitz G, Nesher R (2003) Glucotoxicity and beta-cell failure in type 2 diabetes mellitus. J Pediatr Endocrinol Metab 16:5–22PubMed
3.
go back to reference Poitout V, Robertson RP (2002) Minireview: secondary β-cell failure in type 2 diabetes—a convergence of glucotoxicity and lipotoxicity. Endocrinology 143:339–342PubMedCrossRef Poitout V, Robertson RP (2002) Minireview: secondary β-cell failure in type 2 diabetes—a convergence of glucotoxicity and lipotoxicity. Endocrinology 143:339–342PubMedCrossRef
4.
go back to reference Robertson RP, Harmon J, Tran PO, Poitout V (2004) Beta-cell glucose toxicity, lipotoxicity, and chronic oxidative stress in type 2 diabetes. Diabetes 53(Suppl 1):S119–S124PubMedCrossRef Robertson RP, Harmon J, Tran PO, Poitout V (2004) Beta-cell glucose toxicity, lipotoxicity, and chronic oxidative stress in type 2 diabetes. Diabetes 53(Suppl 1):S119–S124PubMedCrossRef
5.
go back to reference Ivarsson R, Quintens R, Dejonghe S et al (2005) Redox control of exocytosis: regulatory role of NADPH, thioredoxin, and glutaredoxin. Diabetes 54:2132–2142PubMedCrossRef Ivarsson R, Quintens R, Dejonghe S et al (2005) Redox control of exocytosis: regulatory role of NADPH, thioredoxin, and glutaredoxin. Diabetes 54:2132–2142PubMedCrossRef
6.
go back to reference Yoshioka J, Schreiter ER, Lee RT (2006) Role of thioredoxin in cell growth through interactions with signaling molecules. Antioxid Redox Signal 8:2143–2151PubMedCrossRef Yoshioka J, Schreiter ER, Lee RT (2006) Role of thioredoxin in cell growth through interactions with signaling molecules. Antioxid Redox Signal 8:2143–2151PubMedCrossRef
7.
go back to reference Patwari P, Higgins LJ, Chutkow WA, Yoshioka J, Lee RT (2006) The interaction of thioredoxin with Txnip. Evidence for formation of a mixed disulfide by disulfide exchange. J Biol Chem 281:21884–21891PubMedCrossRef Patwari P, Higgins LJ, Chutkow WA, Yoshioka J, Lee RT (2006) The interaction of thioredoxin with Txnip. Evidence for formation of a mixed disulfide by disulfide exchange. J Biol Chem 281:21884–21891PubMedCrossRef
8.
go back to reference Minn AH, Hafele C, Shalev A (2005) Thioredoxin-interacting protein is stimulated by glucose through a carbohydrate response element and induces beta-cell apoptosis. Endocrinology 146:2397–2405PubMedCrossRef Minn AH, Hafele C, Shalev A (2005) Thioredoxin-interacting protein is stimulated by glucose through a carbohydrate response element and induces beta-cell apoptosis. Endocrinology 146:2397–2405PubMedCrossRef
9.
go back to reference Schulze PC, Yoshioka J, Takahashi T, He Z, King GL, Lee RT (2004) Hyperglycemia promotes oxidative stress through inhibition of thioredoxin function by thioredoxin-interacting protein. J Biol Chem 279:30369–30374PubMedCrossRef Schulze PC, Yoshioka J, Takahashi T, He Z, King GL, Lee RT (2004) Hyperglycemia promotes oxidative stress through inhibition of thioredoxin function by thioredoxin-interacting protein. J Biol Chem 279:30369–30374PubMedCrossRef
10.
go back to reference Qi W, Chen X, Gilbert RE et al (2007) High glucose-induced thioredoxin-interacting protein in renal proximal tubule cells is independent of transforming growth factor-beta1. Am J Pathol 171:744–754PubMedCrossRef Qi W, Chen X, Gilbert RE et al (2007) High glucose-induced thioredoxin-interacting protein in renal proximal tubule cells is independent of transforming growth factor-beta1. Am J Pathol 171:744–754PubMedCrossRef
11.
go back to reference Turturro F, Friday E, Welbourne T (2007) Hyperglycemia regulates thioredoxin-ROS activity through induction of thioredoxin-interacting protein (TXNIP) in metastatic breast cancer-derived cells MDA-MB-231. BMC Cancer 7:96PubMedCrossRef Turturro F, Friday E, Welbourne T (2007) Hyperglycemia regulates thioredoxin-ROS activity through induction of thioredoxin-interacting protein (TXNIP) in metastatic breast cancer-derived cells MDA-MB-231. BMC Cancer 7:96PubMedCrossRef
12.
go back to reference Minn AH, Hafele C, Shalev A (2005) Thioredoxin-interacting protein is stimulated by glucose through a carbohydrate response element and induces beta-cell apoptosis. Endocrinology 146:2397–2495PubMedCrossRef Minn AH, Hafele C, Shalev A (2005) Thioredoxin-interacting protein is stimulated by glucose through a carbohydrate response element and induces beta-cell apoptosis. Endocrinology 146:2397–2495PubMedCrossRef
13.
go back to reference Chen J, Saxena G, Mungrue IN, Lusis AJ, Shalev A (2008) Thioredoxin-interacting protein: a critical link between glucose toxicity and beta cell apoptosis. Diabetes 57:938–944PubMedCrossRef Chen J, Saxena G, Mungrue IN, Lusis AJ, Shalev A (2008) Thioredoxin-interacting protein: a critical link between glucose toxicity and beta cell apoptosis. Diabetes 57:938–944PubMedCrossRef
14.
go back to reference Chen J, Hui ST, Couto FM et al (2008) Thioredoxin-interacting protein deficiency induces Akt/Bcl-xL signaling and pancreatic beta-cell mass and protects against diabetes. FASEB J 22:3581–3594PubMedCrossRef Chen J, Hui ST, Couto FM et al (2008) Thioredoxin-interacting protein deficiency induces Akt/Bcl-xL signaling and pancreatic beta-cell mass and protects against diabetes. FASEB J 22:3581–3594PubMedCrossRef
15.
go back to reference Parikh H, Carlsson E, Chutkow WA et al (2007) TXNIP regulates peripheral glucose metabolism in humans. PLoS Med 4:e158PubMedCrossRef Parikh H, Carlsson E, Chutkow WA et al (2007) TXNIP regulates peripheral glucose metabolism in humans. PLoS Med 4:e158PubMedCrossRef
16.
go back to reference Nesher R, Gross DJ, Donath MY, Cerasi E, Kaiser N (1999) Interaction between genetic and dietary factors determines beta-cell function in Psammomys obesus, an animal model of type 2 diabetes. Diabetes 48:731–737PubMedCrossRef Nesher R, Gross DJ, Donath MY, Cerasi E, Kaiser N (1999) Interaction between genetic and dietary factors determines beta-cell function in Psammomys obesus, an animal model of type 2 diabetes. Diabetes 48:731–737PubMedCrossRef
17.
go back to reference Kaiser N, Corcos AP, Tur-Sinai A, Ariav Y, Cerasi E (1988) Monolayer culture of adult rat pancreatic islets on extracellular matrix: long term maintenance of differentiated B cell function. Endocrinology 123:834–840PubMedCrossRef Kaiser N, Corcos AP, Tur-Sinai A, Ariav Y, Cerasi E (1988) Monolayer culture of adult rat pancreatic islets on extracellular matrix: long term maintenance of differentiated B cell function. Endocrinology 123:834–840PubMedCrossRef
18.
go back to reference Schulze PC, Liu H, Choe E et al (2006) Nitric oxide-dependent suppression of thioredoxin-interacting protein expression enhances thioredoxin activity. Arterioscler Thromb Vasc Biol 26:2666–2672PubMedCrossRef Schulze PC, Liu H, Choe E et al (2006) Nitric oxide-dependent suppression of thioredoxin-interacting protein expression enhances thioredoxin activity. Arterioscler Thromb Vasc Biol 26:2666–2672PubMedCrossRef
19.
go back to reference Cahuana GM, Tejedo JR, Hmadcha A et al (2008) Nitric oxide mediates the survival action of IGF-1 and insulin in pancreatic beta cells. Cell Signal 20:301–310PubMedCrossRef Cahuana GM, Tejedo JR, Hmadcha A et al (2008) Nitric oxide mediates the survival action of IGF-1 and insulin in pancreatic beta cells. Cell Signal 20:301–310PubMedCrossRef
20.
go back to reference Hui ST, Andres AM, Miller AK et al (2008) Txnip balances metabolic and growth signaling via PTEN disulfide reduction. Proc Natl Acad Sci U S A 105:3921–3926PubMedCrossRef Hui ST, Andres AM, Miller AK et al (2008) Txnip balances metabolic and growth signaling via PTEN disulfide reduction. Proc Natl Acad Sci U S A 105:3921–3926PubMedCrossRef
21.
go back to reference Chen J, Couto FM, Minn AH, Shalev A (2006) Exenatide inhibits beta-cell apoptosis by decreasing thioredoxin-interacting protein. Biochem Biophys Res Commun 346:1067–1074PubMedCrossRef Chen J, Couto FM, Minn AH, Shalev A (2006) Exenatide inhibits beta-cell apoptosis by decreasing thioredoxin-interacting protein. Biochem Biophys Res Commun 346:1067–1074PubMedCrossRef
22.
go back to reference Yechoor VK, Patti ME, Ueki K et al (2004) Distinct pathways of insulin-regulated versus diabetes-regulated gene expression: an in vivo analysis in MIRKO mice. Proc Natl Acad Sci U S A 101:16525–16530PubMedCrossRef Yechoor VK, Patti ME, Ueki K et al (2004) Distinct pathways of insulin-regulated versus diabetes-regulated gene expression: an in vivo analysis in MIRKO mice. Proc Natl Acad Sci U S A 101:16525–16530PubMedCrossRef
23.
go back to reference Saitoh T, Tanaka S, Koike T (2001) Rapid induction and Ca(2+) influx-mediated suppression of vitamin D3 up-regulated protein 1 (VDUP1) mRNA in cerebellar granule neurons undergoing apoptosis. J Neurochem 78:1267–1276PubMedCrossRef Saitoh T, Tanaka S, Koike T (2001) Rapid induction and Ca(2+) influx-mediated suppression of vitamin D3 up-regulated protein 1 (VDUP1) mRNA in cerebellar granule neurons undergoing apoptosis. J Neurochem 78:1267–1276PubMedCrossRef
25.
go back to reference de Candia P, Blekhman R, Chabot AE, Oshlack A, Gilad Y (2008) A combination of genomic approaches reveals the role of FOXO1a in regulating an oxidative stress response pathway. PLoS ONE 3:e1670PubMedCrossRef de Candia P, Blekhman R, Chabot AE, Oshlack A, Gilad Y (2008) A combination of genomic approaches reveals the role of FOXO1a in regulating an oxidative stress response pathway. PLoS ONE 3:e1670PubMedCrossRef
26.
go back to reference Sargsyan E, Ortsater H, Thorn K, Bergsten P (2008) Diazoxide-induced beta-cell rest reduces endoplasmic reticulum stress in lipotoxic beta-cells. J Endocrinol 199:41–50PubMedCrossRef Sargsyan E, Ortsater H, Thorn K, Bergsten P (2008) Diazoxide-induced beta-cell rest reduces endoplasmic reticulum stress in lipotoxic beta-cells. J Endocrinol 199:41–50PubMedCrossRef
27.
go back to reference Weyer C, Bogardus C, Mott DM, Pratley RE (1999) The natural history of insulin secretory dysfunction and insulin resistance in the pathogenesis of type 2 diabetes mellitus. J Clin Invest 104:787–794PubMedCrossRef Weyer C, Bogardus C, Mott DM, Pratley RE (1999) The natural history of insulin secretory dysfunction and insulin resistance in the pathogenesis of type 2 diabetes mellitus. J Clin Invest 104:787–794PubMedCrossRef
28.
go back to reference Cerasi E, Boitard C, Efendic S, Ferrannini E, Henquin JC, Steiner DF (2001) The islet in type 2 diabetes: back to center stage. Diabetes 50(Suppl 1):S1–S3PubMedCrossRef Cerasi E, Boitard C, Efendic S, Ferrannini E, Henquin JC, Steiner DF (2001) The islet in type 2 diabetes: back to center stage. Diabetes 50(Suppl 1):S1–S3PubMedCrossRef
29.
go back to reference Nesher R, Della Casa L, Litvin Y et al (1987) Insulin deficiency and insulin resistance in type 2 (non-insulin-dependent) diabetes: quantitative contributions of pancreatic and peripheral responses to glucose homeostasis. Eur J Clin Invest 17:266–274PubMedCrossRef Nesher R, Della Casa L, Litvin Y et al (1987) Insulin deficiency and insulin resistance in type 2 (non-insulin-dependent) diabetes: quantitative contributions of pancreatic and peripheral responses to glucose homeostasis. Eur J Clin Invest 17:266–274PubMedCrossRef
30.
go back to reference Kahn SE (2000) The importance of the β-cell in the pathogenesis of type 2 diabetes mellitus. Am J Med 198:2S–8SCrossRef Kahn SE (2000) The importance of the β-cell in the pathogenesis of type 2 diabetes mellitus. Am J Med 198:2S–8SCrossRef
31.
go back to reference Poitout V, Robertson RP (2007) Glucolipotoxicity: fuel excess and beta-cell dysfunction. Endocr Rev 29:351–366PubMedCrossRef Poitout V, Robertson RP (2007) Glucolipotoxicity: fuel excess and beta-cell dysfunction. Endocr Rev 29:351–366PubMedCrossRef
32.
go back to reference Gunton JE, Kulkarni RN, Yim S et al (2005) Loss of ARNT/HIF1beta mediates altered gene expression and pancreatic-islet dysfunction in human type 2 diabetes. Cell 122:337–349PubMedCrossRef Gunton JE, Kulkarni RN, Yim S et al (2005) Loss of ARNT/HIF1beta mediates altered gene expression and pancreatic-islet dysfunction in human type 2 diabetes. Cell 122:337–349PubMedCrossRef
33.
go back to reference Chutkow WA, Patwari P, Yoshioka J, Lee RT (2008) Thioredoxin-interacting protein (Txnip) is a critical regulator of hepatic glucose production. J Biol Chem 283:2397–2406PubMedCrossRef Chutkow WA, Patwari P, Yoshioka J, Lee RT (2008) Thioredoxin-interacting protein (Txnip) is a critical regulator of hepatic glucose production. J Biol Chem 283:2397–2406PubMedCrossRef
34.
go back to reference Yoshioka J, Imahashi K, Gabel SA et al (2007) Targeted deletion of thioredoxin-interacting protein regulates cardiac dysfunction in response to pressure overload. Circ Res 101:1328–1338PubMedCrossRef Yoshioka J, Imahashi K, Gabel SA et al (2007) Targeted deletion of thioredoxin-interacting protein regulates cardiac dysfunction in response to pressure overload. Circ Res 101:1328–1338PubMedCrossRef
Metadata
Title
Insulin counteracts glucotoxic effects by suppressing thioredoxin-interacting protein production in INS-1E beta cells and in Psammomys obesus pancreatic islets
Authors
M. Shaked
M. Ketzinel-Gilad
Y. Ariav
E. Cerasi
N. Kaiser
G. Leibowitz
Publication date
01-04-2009
Publisher
Springer-Verlag
Published in
Diabetologia / Issue 4/2009
Print ISSN: 0012-186X
Electronic ISSN: 1432-0428
DOI
https://doi.org/10.1007/s00125-009-1274-2

Other articles of this Issue 4/2009

Diabetologia 4/2009 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine